Nordion (NDZ +9%) ramps higher this morning after the company says it will divest its Target...

|About: Nordion Inc. (NDZ)|By:, SA News Editor

Nordion (NDZ +9%) ramps higher this morning after the company says it will divest its Target Therapies business to BTG for around $200M. That means, after fees, NDZ should rake-in nearly $185M on the closing. The sale its part of the company's larger strategic reorganization, and it's hefty price tag for a business whose sole product is its targeted liver cancer therapy, TheraSphere.